ExcitingAds! Multiple Myelome

Antibodies against human tweak and uses thereof

Fri, 18 May 2012 00:00:00 -0700

The invention provides antibodies binding to TWEAK, including anti-TWEAK antibodies comprising a heavy chain variable domain CDR3 (CDR3H) selected from the group consisting of SEQ ID NO: 8, 16 or 24. The invention provides anti-TWEAK antibodies which are useful for the treatment of cancer, autoimmune diseases, rheumatoid arthritis, psoratic arthritis, muscle...

Methods for inducing a sustained immune response against a b-cell idiotype using autologous anti-idiotypic vaccines

Fri, 11 May 2012 00:00:00 -0700

The present invention relates to methods of inducing and maintaining an immune response against a B-cell idiotype in a subject using an autologous anti-idiotypic vaccine. In one embodiment, the immune response is induced and maintained for treatment of a B-cell derived malignancy selected from among non-Hodgkin's lymphoma. Hodgkin's lymphoma, chronic lymphocytic...

Use of specific peptides in the preparation of a medicament for the treatment of monoclonal gammopathy of undetermined significance (mgus) or of smoldering multiple myeloma (smm)

Fri, 11 May 2012 00:00:00 -0700

The present invention relates to the use of a peptide comprising or essentially consisting of a sequence motif as shown in SEQ ID NO: 1 for the preparation of a medicament for the treatment of Monoclonal Gammopathy of Undetermined Significance (MGUS) or of Smoldering Multiple Myeloma (SMM). Moreover, the present invention...

Substituted phenoxy n-alkylated thiazolidinediones as estrogen related receptor-alpha modulators

Fri, 04 May 2012 00:00:00 -0700

methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen...

Method for treatment of blood tumor using anti-tim-3 antibody

Fri, 27 Apr 2012 00:00:00 -0700

Disclosed is a therapeutic method comprising administering a TIM-3 antibody to a subject who is suspected to be suffering from blood tumor and in whom TIM-3 has been expressed in a Lin(−)CD34(+)CD38(−) cell fraction of bone marrow or peripheral blood or a subject who has been received any treatment for blood...

Anti-icam-1 antibody, uses and methods

Fri, 13 Apr 2012 00:00:00 -0700

The present invention relates to an antibody or an antigen-binding fragment thereof with binding specificity for ICAM-1, and to the use thereof in medicine for the treatment of cancers, such as multiple myeloma....

Lpa receptor antagonist

Fri, 13 Apr 2012 00:00:00 -0700

(wherein the symbols are as defined in the description), or a non-toxic salt thereof. This compound engages in LPA receptor bonding and antagonism and hence is useful in the prevention and/or treatment of urinary system disease (symptom with prostatic hypertrophy or neurogenic bladder dysfunction disease, symptom to be caused by spinal...

Modulation of autophagy and and serotonin for treatment of multiple myeloma related diseases

Fri, 30 Mar 2012 00:00:00 -0700

THE INVENTION RELATES TO compounds, proteins and methods of treatment therewith. Aspects of embodiments of the invention further relates to compounds and methods of treatment for bone, bone marrow, and bone tissue....

Generation and profiling of fully human hucal gold®-derived therapeutic antibodies specific for human cd38

Fri, 30 Mar 2012 00:00:00 -0700

The present invention provides novel methods for using recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for CD38, which plays an integral role in various disorders or conditions. These methods take advantage of newly discovered antibodies and surprising properties of such antibodies, such as...

Combination therapy for the treatment of multiple myeloma

Fri, 23 Mar 2012 00:00:00 -0700

The present invention provides a method for treating multiple myeloma in a subject, comprising the step of administering to the subject a combination of COMPOUND 1 and bortezomib. The invention further provides a method for treating multiple myeloma in a subject, comprising the step of administering to the subject a combination...

Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38

Fri, 02 Mar 2012 00:00:00 -0800

The present invention provides novel antibodies and functional fragments thereof specific for CD38, and methods of using the same for the treatment of diseases associated with CD38 expression, including hematological malignancies such as multiple myeloma....

Identification of antigenic peptides from multiple myeloma cells

Fri, 24 Feb 2012 00:00:00 -0800

Multiple myeloma (MM) is a clonal B cell malignancy and remains essentially incurable by conventional anti-tumor therapy. Patients with MM have a median survival of only three years. MM is characterized by proliferation and accumulation of mature plasma cells in the bone marrow (BM) leading to bone destruction, BM failure, anemia,...

Identification of antigenic peptides from multiple myeloma cells

Fri, 24 Feb 2012 00:00:00 -0800

Identification of antigenic peptides from multiple myeloma cells

Fri, 24 Feb 2012 00:00:00 -0800

Methods of treating multiple myeloma using melphalan, prednisone and lenalidomide

Fri, 10 Feb 2012 00:00:00 -0800

Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding...

Uses of bortezomib in predicting survival in multiple myeloma patients

Fri, 20 Jan 2012 00:00:00 -0800

The present invention provides a method of predicting outcome of treatment for multiple myeloma based on determining certain cytogenetic anomalies and considering gene expression profiling risks. Also provided are statistical methods employed to define variables independently impacting outcomes. Further provided is method of treatment of myeloma patients....

Use of 5ahq and bortezomib for the treatment of hematological diseases

Fri, 30 Dec 2011 00:00:00 -0800

The disclosure provides methods and compositions for treating hematological malignancies. In particular, the disclosure provides methods and compositions for treating leukemia, lymphoma and multiple myeloma using bortezomit and 5AHQ (5-ammo-8-hydroxyqumolme) and related compounds that bind non-competitively to an alpha unit of 2OS proteasome and inhibit proteasome activity Kits and commercial packages...

Diagnosis, prognosis and identification of potential therapeutic targets of multiple myeloma based on gene expression profiling

Fri, 30 Dec 2011 00:00:00 -0800

Provided herein is a method for gene expression profiling multiple myeloma patients into distinct subgroups via DNA hybridization and hierarchical clustering analysis of the hybridization data where the results may further be used to identify therapeutic gene targets. Also provided is a method for controlling bone loss in an individual via...

Methods for determining a prognosis in multiple myeloma

Fri, 09 Dec 2011 00:00:00 -0800

Methods for determining a prognosis in multiple myeloma are disclosed, and in particular to methods that are capable of identifying patients with a poor prognosis and/or for determining the likelihood of a patient responding to a particular treatment. The methods identify myeloma samples having homozygous deletions in cell death genes, with...

Prodrug of an ice inhibitor

Fri, 09 Dec 2011 00:00:00 -0800

Compound I is useful for treating IL-1 mediated diseases such as rheumatoid arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, inflammatory peritonitis, septic shock, pancreatitis, traumatic brain injury, organ transplant rejection, osteoarthritis, asthma, psoriasis, Alzheimer's disease, myocardial infarction, congestive heart failure, Huntington's disease, atherosclerosis, atopic dermatitis, leukemias and related disorders, myelodysplastic...

Substituted thiazolidinedione indazoles, indoles and benzotriazoles as estrogen-related receptor-a modulators

Fri, 02 Dec 2011 00:00:00 -0800

Treatment of renal dysfunction and multiple myeloma using pacap compounds

Fri, 25 Nov 2011 00:00:00 -0800

The present invention relates to methods and compositions for the treatment, management, or prevention of multiple myeloma and/or renal dysfunction in mammals. The methods of the invention comprise the administration of an effective amount of one or more pituitary adenylate cyclase activating polypeptide (“PACAP”) compounds, which includes PACAP, vasoactive intestinal peptide...

Nuclear export inhibitors of topoisomerase ii alpha

Fri, 11 Nov 2011 00:00:00 -0800

A method of treating cancer in a subject comprising the step of administering to the subject in need thereof an effective amount of a combination of a compound that binds a nuclear export signal (NES inhibitor) on topoisomerase IIα and a topoisomerase inhibitor. Twenty small molecule inhibitors (SMI) that bind to...

Anti-cd38 human antibodies and uses thereof

Fri, 04 Nov 2011 00:00:00 -0700

The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for CD38, which plays an integral role in various disorders or conditions. These antibodies, accordingly, can be used to treat, for example, hematological malignancies such as multiple myeloma. Antibodies of the invention...

Crystalline form of lenalidomide and a process for its preparation

Fri, 28 Oct 2011 00:00:00 -0700

The present invention relates to a novel crystalline form of lenalidomide having formula (I) and chemically known as 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione. The present invention further relates to a process for the preparation of said novel form and its use in pharmaceutical preparations for the treatment of autoimmune disease, inflammation, inflammatory disease and diseases...

Compounds and methods for kinase modulation, and indications therefor

Fri, 28 Oct 2011 00:00:00 -0700

Compounds and salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof and uses thereof are described. In certain aspects and embodiments, the described compounds or salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof are active on one or more of Fms, Kit, Flt3, TrkA, TrkB and TrkC kinase...

Compositions, kits, and methods for the diagnosis, prognosis, and monitoring of cancer using golph3

Fri, 28 Oct 2011 00:00:00 -0700

The present invention is based, in part, on the discovery that GOLPH3 plays a role in cancer, including lung, ovarian, pancreatic, liver, breast, prostate, and colon carcinomas, as well as melanoma and multiple myeloma. Accordingly, the invention relates to compositions, kits, and methods for diagnosing, prognosing, and monitoring cancer, e.g., lung,...

Novel anti-cd38 antibodies for the treatment of cancer

Fri, 28 Oct 2011 00:00:00 -0700

Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to CD38, are capable of killing CD38+ cells by apoptosis, antibody-dependent cell-mediated cytotoxicity (ADCC), and/or complement-dependent cytotoxicity (CDC). Said antibodies and fragments thereof may be used in the treatment of tumors that...

Compositions and method for the treatment of multiple myeloma

Fri, 21 Oct 2011 00:00:00 -0700

The disclosure provides compositions and methods for treating multiple myeloma. In some embodiments, the compositions comprise (E)-3-hydroxy-21-[2′-(N,N-dimethylamino)ethoxy]-19-norpregna-1,3,5(10),17(20)-tetraene or a pharmaceutically acceptable salt or prodrug thereof and a pharmaceutical carrier....

Compositions and methods for inhibiting ezh2

Fri, 14 Oct 2011 00:00:00 -0700

The present invention relates to therapeutic targets for cancer. In particular, the present invention relates to small molecules and nucleic acids that target EZH2 expression in cancer (e.g., prostate cancer, breast cancer, other solid tumors, multiple myeloma)....